Centessa Pharmaceuticals PLC
CNTA16.590USD
-0.220-1.31%
시장 운영 시간 （ET）시세는 15분 지연됩니다
2.22B시가총액
손실P/E TTM
자세한 내용은 Centessa Pharmaceuticals PLC 회사
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
회사 정보
종목 코드 CNTA
회사 이름Centessa Pharmaceuticals PLC
상장일May 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
직원 수77
유형Depository Receipt
회계 연도 종료May 28
주소3rd Floor
도시ALTRINCHAM
증권 거래소NASDAQ Global Select Consolidated
국가United Kingdom
우편 번호WA14 2DT
전화447391789784
웹사이트https://www.centessa.com/
종목 코드 CNTA
상장일May 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen Anderson
Ms. Karen Anderson
Chief People Officer
Chief People Officer
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, Jul 2
마지막 업데이트: Wed, Jul 2
주주
주주 유형
주주
주주
비율
Medicxi Ventures (UK) LLP
14.94%
Index Ventures SA
7.46%
General Atlantic LLC
7.25%
Adage Capital Management, L.P.
5.20%
Janus Henderson Investors
4.43%
Other
60.72%
주주
주주
비율
Medicxi Ventures (UK) LLP
14.94%
Index Ventures SA
7.46%
General Atlantic LLC
7.25%
Adage Capital Management, L.P.
5.20%
Janus Henderson Investors
4.43%
Other
60.72%
주주 유형
주주
비율
Hedge Fund
23.53%
Venture Capital
23.05%
Investment Advisor
19.40%
Investment Advisor/Hedge Fund
15.34%
Private Equity
10.46%
Research Firm
2.54%
Individual Investor
0.50%
Endowment Fund
0.06%
Other
5.12%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
220
133.64M
100.03%
-11.01M
2025Q1
222
135.75M
101.62%
-10.84M
2024Q4
187
130.97M
99.33%
-6.00M
2024Q3
166
123.88M
97.57%
+8.26M
2024Q2
145
101.97M
89.71%
-3.69M
2024Q1
140
90.07M
89.09%
-8.60M
2023Q4
126
85.94M
86.60%
-9.82M
2023Q3
125
84.37M
86.02%
-11.03M
2023Q2
135
82.21M
85.98%
-8.96M
2023Q1
131
78.75M
82.92%
-8.68M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Medicxi Ventures (UK) LLP
19.96M
14.94%
--
--
Apr 24, 2025
Index Ventures SA
9.96M
7.46%
--
--
Apr 24, 2025
General Atlantic LLC
9.68M
7.25%
--
--
Apr 24, 2025
Adage Capital Management, L.P.
6.95M
5.2%
+1.83M
+35.85%
Mar 31, 2025
Janus Henderson Investors
5.92M
4.43%
+1.01M
+20.63%
Mar 31, 2025
T. Rowe Price Associates, Inc.
5.34M
4%
-22.05K
-0.41%
Mar 31, 2025
First Light Asset Management, LLC
4.87M
3.65%
-931.06K
-16.04%
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.33M
3.24%
+835.61K
+23.88%
Mar 31, 2025
Avoro Capital Advisors LLC
4.05M
3.03%
+4.05M
--
Mar 31, 2025
VV Manager LLC
3.93M
2.95%
--
--
Dec 31, 2024
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
SPDR S&P International Small Cap ETF
0.09%
iShares Biotechnology ETF
0.07%
T Rowe Price Small-Mid Cap ETF
0.05%
Fidelity Nasdaq Composite Index ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.98%
ProShares Ultra Nasdaq Biotechnology
비율0.14%
Invesco Nasdaq Biotechnology ETF
비율0.14%
SPDR S&P International Small Cap ETF
비율0.09%
iShares Biotechnology ETF
비율0.07%
T Rowe Price Small-Mid Cap ETF
비율0.05%
Fidelity Nasdaq Composite Index ETF
비율0%
First Trust IPOX Europe Equity Opportunities ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
